ILLUMINA Aktie

>ILLUMINA Aktienkurs

109.5 EUR +0.1% (TradegateBSX)

Ask: 110.48 EUR / 280 Stück

Bid: 110.26 EUR / 280 Stück

Tagesumsatz: 282 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ILLUMINA Aktie über LYNX handeln

Intraday

1 Jahr

>ILLUMINA Performance

1 Woche: +7,0%

1 Monat: -2,2%

3 Monate: -4,0%

6 Monate: +27,3%

1 Jahr: +57,6%

laufendes Jahr: -4,2%

>ILLUMINA Aktie

Name:

ILLUMINA INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4523271090 / 927079

Symbol/ Ticker:

ILU (Frankfurt) / ILMN (NASDAQ)

Kürzel:

FRA:ILU, ETR:ILU, ILU:GR, NASDAQ:ILMN

Index:

S&P500

Webseite:

http://www.illumina.com/

Profil:

Illumina, Inc. develops, manufactures, and markets sequencing- and array-based solutions for genetic and genomic analysis worldwide, including in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company provides..
>Volltext..

Marktkapitalisierung:

16773.35 Mio. EUR

Unternehmenswert:

17556.3 Mio. EUR

Umsatz:

3760.67 Mio. EUR

EBITDA:

1009.26 Mio. EUR

Nettogewinn:

736.37 Mio. EUR

Gewinn je Aktie:

4.75 EUR

Schulden:

2211.7 Mio. EUR

Liquide Mittel:

1228.43 Mio. EUR

Operativer Cashflow:

934.75 Mio. EUR

Bargeldquote:

1.03

Umsatzwachstum:

-12.48%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ILLUMINA

Letzte Datenerhebung:

05.04.26

>ILLUMINA Kennzahlen

Aktien/ Unternehmen:

Aktien: 152.9 Mio. St.

Frei handelbar: 97.19%

Leerverk. Aktien: 4.73%

Rückkaufquote: 3.61%

Mitarbeiter: 8600

Umsatz/Mitarb.: 0.44 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 7.83%

Bewertung:

KGV: 23.49

KGV lG: 24.57

KUV: 4.46

KBV: 7.21

PEG-Ratio: -

EV/EBITDA: 17.4

Rentabilität:

Bruttomarge: 67.08%

Gewinnmarge: 19.58%

Operative Marge: 20.59%

Managementeffizenz:

Gesamtkaprendite: 13.13%

Eigenkaprendite: 33.36%

>ILLUMINA Peer Group

Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege

>ILLUMINA Chart & Kurs - NASDAQ

>ILLUMINA News

02.04.26 - 15:09	Illumina Announces Changes to Board of Directors (PR Newswire)
	David P. King nominated to support next phase of growth and innovation; Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the Board SAN DIEGO, April 2, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced changes to its Board of Directors. Frances Arnold,......

24.03.26 - 16:30	Here′s Why Illumina (ILMN) is a Strong Growth Stock (Zacks)
	Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

19.03.26 - 20:15	ILMN Stock Gains Following Expanded Collaboration With Labcorp (Zacks)
	Illumina gains after expanding Labcorp collaboration to boost NGS oncology adoption, broaden testing access, and drive growth in precision cancer care....

18.03.26 - 17:30	Illumina Expands Collaboration With Labcorp To Advance Precision Oncology (AFX)
	SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing ......

18.03.26 - 14:18	Illumina and Labcorp expand collaboration to broaden access to precision oncology testing (PR Newswire)
	SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation......

16.03.26 - 14:18	Illumina advances preventive genomics through strategic consortium with Veritas Genetics (PR Newswire)
	New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention SAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas......

11.03.26 - 15:00	Illumina Stock Climbs 44.8% in a Year: What′s Driving the Rally? (Zacks)
	ILMN stock surges 44.8% in a year, fueled by NovaSeq X sequencing demand, broader NGS testing adoption, multiomics expansion and improving margins....

09.03.26 - 16:30	Here′s Why Illumina (ILMN) is a Strong Momentum Stock (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

05.03.26 - 15:16	Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering (PR Newswire)
	Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC......

04.03.26 - 17:30	Why Illumina (ILMN) is a Top Growth Stock for the Long-Term (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

04.03.26 - 05:18	Illumina stellt auf TD Cowen Konferenz Wachstums- und Innovationsstrategie vor (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 15:18	Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida (PR Newswire)
	Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified......

26.02.26 - 18:15	TEM vs. ILMN: Which MedTech Stock Offers Greater Upside? (Zacks)
	Tempus posts 83% Q4 revenue growth and a 49.6% implied upside as AI-driven oncology gains steam - can it outpace Illumina in 2026?...

25.02.26 - 15:18	Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics (PR Newswire)
	At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing,......

25.02.26 - 02:01	Insiderhandel: Chief Legal Officer verkauft Aktien von Illumina im Wert von 155216 USD (Insiderkauf)
	Davies, Scott M. - Vorstand - Tag der Transaktion: 2026-02-20...

24.02.26 - 18:18	Illumina launches TruPath Genome, setting a new standard in genomic insight (PR Newswire)
	TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinical Labs is among first to adopt product, which was previously known as "constellation......

23.02.26 - 15:18	Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility (PR Newswire)
	40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 23,......

19.02.26 - 02:01	Insiderhandel: SVP, Chief People Officer verkauft Aktien von Illumina im Wert von 275347 USD (Insiderkauf)
	Leckman, Patricia - Vorstand - Tag der Transaktion: 2026-02-18...

17.02.26 - 21:12	Illumina To Webcast Upcoming Investor Conference (PR Newswire)
	SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference TD Cowen 46th Annual Health Care Conference 2026 on March 3, 2026 The fireside......

12.02.26 - 16:00	Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips (Zacks)
	ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram